Fasting Before Contrast-Enhanced CT May Not Be Necessary for Some Patients
The number of adverse events related to contrast-enhanced CT are not statistically different between patients who fasted or who ate beforehand.
It may not be necessary for cancer patients to fast prior to undergoing contrast-enhanced CT, according to a study published in the American Journal of Roentgenology.
Researchers from Brazil performed a prospective study to evaluate the effects of preparative fasting prior to contrast-enhanced CTs for patients with cancer. A total of 3,206 patients were randomly assigned to one of two groups; 1,619 fasted for at least 4 hours prior to their procedure and 1,587 consumed a light meal before undergoing the scan.
The results showed 45 patients (1.5 percent) in the fasting group reported adverse events, compared with 30 patients (0.9 percent) in the non-fasting group. The most common adverse events were:
• Nausea: 32 patients
• Weakness: 12 patients
• Vomiting: 5 patients
The authors noted that the frequency of symptoms between the two groups did not differ statistically significantly.
They concluded that among their sample group, there were few adverse reactions associated with eating a light meal before undergoing a CT scan with an IV contrast agent. “These results support the idea that preparation for contrast-enhanced CT can be simplified, decreasing the discomfort and inconvenience experienced by patients,” they wrote.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
